Doxorubicin has 19 known drug interactions based on U.S. FDA drug labeling data. Of these, 5 are contraindicated combinations that should be avoided entirely. 8 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Abacavir , Lamivudine And Zidovudine, Dexrazoxane, Lamivudine And Zidovudine. Patients taking Doxorubicin should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 19
- Contraindicated
- 5
- Major
- 8
- Moderate
- 6
Contraindicated (5)
- Doxorubicin + Abacavir , Lamivudine And Zidovudine— Concomitant use with zidovudine should be avoided due to demonstrated in vitro antagonistic relationship.
- Doxorubicin + Dexrazoxane— Do not administer as a cardioprotectant at initiation of doxorubicin-containing chemotherapy. Resulted in significantly …
- Doxorubicin + Lamivudine And Zidovudine— Concomitant use should be avoided due to demonstrated antagonistic relationship with zidovudine in vitro.
- Doxorubicin + Trastuzumab— Concomitant use results in increased risk of cardiac dysfunction. Do not administer in combination. Trastuzumab may pers…
- Doxorubicin + Zidovudine— Concomitant use should be avoided due to demonstrated antagonistic relationship in vitro.
Major (8)
- Doxorubicin + Allopurinol— Increases bone marrow suppression in patients with neoplastic disease (except leukemia). Blood count monitoring recommen…
- Doxorubicin + Anthracycline— Therefore, avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab when possible. If anthracycli…
- Doxorubicin + Daunorubicin Hydrochloride— Previous doxorubicin use increases risk of cardiotoxicity with daunorubicin. Contraindicated if maximum cumulative doses…
- Doxorubicin + Ganciclovir Sodium— Associated with myelosuppression or nephrotoxicity; coadministration should be considered only if potential benefits out…
- Doxorubicin + Mercaptopurine— Doxorubicin may potentiate 6-mercaptopurine-induced hepatotoxicity, resulting in hepatic dysfunction manifested by incre…
- Doxorubicin + Paclitaxel— Plasma levels of doxorubicin and its active metabolite doxorubicinol may be increased when used in combination with pacl…
- Doxorubicin + Valganciclovir— Associated with myelosuppression or nephrotoxicity. Coadministration should be considered only if potential benefits out…
- Doxorubicin + Valganciclovir Hydrochloride— Co-administration with valganciclovir should be considered only if potential benefits outweigh risks due to potential fo…
Moderate (6)
- Doxorubicin + Carbamazepine— CYP3A4 inducer that decreases carbamazepine plasma levels. Carbamazepine levels and/or dosage adjustment may be necessar…
- Doxorubicin + Fosphenytoin Sodium— May decrease phenytoin serum levels; dose adjustment may be required.
- Doxorubicin + Gadobenate Dimeglumine— MultiHance may compete for MOAT transporter and prolong systemic exposure of doxorubicin.
- Doxorubicin + Ganciclovir— Associated with myelosuppression or nephrotoxicity. Coadministration considered only if benefits outweigh risks.
- Doxorubicin + Phenytoin— May decrease phenytoin serum levels; monitoring of phenytoin levels recommended.
- Doxorubicin + Phenytoin Sodium— May decrease phenytoin serum levels; monitoring of phenytoin levels recommended.